

STATE OF RHODE ISLAND



Department of Behavioral Healthcare, Developmental Disabilities & Hospitals
OFFICE OF THE DIRECTOR
14 Harrington Road
Cranston, RI 02920-3080

TEL: (401) 462-3201
FAX: (401) 462-3204
TDD: (401) 462-6087

March 12, 2026

The Honorable Susan R. Donovan, Chair
House Committee on Health and Human Services
State House
Providence, RI 02903

RE: 2026 — H 7535 - An Act Relating to Food and Drugs – Compassionate Access to Medical Cannabis Act

Dear Chair Donovan:

Please accept this letter of concern regarding H 7535 which would require healthcare facilities as defined under § 23-15-2 to allow terminally ill patients to use medical cannabis within the facility and specifies the conditions for such use.

BHDDH is committed to ensuring the health and safety of all individuals under our care, including those who are patients at Eleanor Slater Hospital (ESH). While we acknowledge the admirable intent of this legislation to provide compassionate access to medical cannabis for terminally ill patients, we are deeply concerned about the practical implementation within a hospital setting, particularly given the implications for a hospital violating federal laws and/or regulations.

Cannabis remains a Schedule I substance under federal law, a designation which would place healthcare facilities as defined under § 23-15-2 including Eleanor Slater Hospital (ESH) in a very difficult position as H 7535 expressly disallows a healthcare facility from prohibiting patient use of medical cannabis based solely on the Schedule I designation.

Hospitals receiving Medicare and Medicaid funding are required to comply with the provisions of the Conditions of Participation (CoP) pursuant to 42 CFR § 482.25. Permitting the use of a Schedule I drug within a hospital would constitute a violation of the CoP. As healthcare facility accrediting bodies such as The Joint Commission are required to follow federal law, compliance with the provisions of H 7535 would subject ESH to the potential loss of accreditation.

Allowing hospitals to suspend compliance with H 7535 only after a federal regulating agency or the United States Department of Justice undertakes an enforcement action against a healthcare facility; or if a federal agency, including Center for Medicare and Medicaid Services (CMS), issues a rule or provides notification expressly prohibiting the use of medical cannabis within a healthcare facility, would require hospitals to violate current federal laws and/or regulations.

Compliance with H 7535, if enacted, would therefore jeopardize federal funding, including Medicare and Medicaid, which are critical for the operation of ESH and the provision of care to our patients. Federal enforcement actions also could be taken against ESH, its staff, and the State.

Thank you for the opportunity to express BHDDH's concerns regarding H 7535.

Sincerely,



Richard Leclerc
Director

cc: Honorable Members of the House Committee on Health & Human Services
Nicole McCarty, Esquire, Chief Legal Counsel to the Speaker of the House
Lynne Urbani, Director of House Policy